RATIONALE: Ketamine is an N-methyl-D: -aspartate (NMDA) receptor antagonist with psychotogenic effects and for which there are diverse reports of whether pleasant or unpleasant dreams result during anaesthesia, post-operatively or after sub-anaesthetic use. OBJECTIVE: To assess in healthy volunteers the incidence of unpleasant dreams over the three nights after receiving a sub-anaesthetic dose of ketamine, in comparison to placebo, and with retrospective home nightmare frequency as a covariate. METHOD:Thirty healthy volunteers completed questionnaires about retrospective home dream recall and were then given either ketamine (n = 19, males = 9, mean age = 23.5 years; mean ketamine blood plasma = 175.29 ng/mL) orplacebo (n = 11, males = 5, mean age = 25.4 years). Dream recall and pleasantness/unpleasantness of dream content were recorded by questionnaire at home for the three nights after infusion. RESULTS:Ketamine resulted in significantly more mean dream unpleasantness relative to placebo and caused a threefold increase in the odds ratio for the incidence of an unpleasant dream. The number of dreams reported over the three nights did not differ between the groups. The incidence of unpleasant dreams after ketamine use was predicted by retrospectively assessed nightmare frequency at home. CONCLUSIONS:Ketamine causes unpleasant dreams over the three post-administration nights. This may be evidence of a residual psychotogenic effect that is not found on standard self-report symptomatology measures or a result of disturbed sleep electrophysiology.
RCT Entities:
RATIONALE: Ketamine is an N-methyl-D: -aspartate (NMDA) receptor antagonist with psychotogenic effects and for which there are diverse reports of whether pleasant or unpleasant dreams result during anaesthesia, post-operatively or after sub-anaesthetic use. OBJECTIVE: To assess in healthy volunteers the incidence of unpleasant dreams over the three nights after receiving a sub-anaesthetic dose of ketamine, in comparison to placebo, and with retrospective home nightmare frequency as a covariate. METHOD: Thirty healthy volunteers completed questionnaires about retrospective home dream recall and were then given either ketamine (n = 19, males = 9, mean age = 23.5 years; mean ketamine blood plasma = 175.29 ng/mL) or placebo (n = 11, males = 5, mean age = 25.4 years). Dream recall and pleasantness/unpleasantness of dream content were recorded by questionnaire at home for the three nights after infusion. RESULTS:Ketamine resulted in significantly more mean dream unpleasantness relative to placebo and caused a threefold increase in the odds ratio for the incidence of an unpleasant dream. The number of dreams reported over the three nights did not differ between the groups. The incidence of unpleasant dreams after ketamine use was predicted by retrospectively assessed nightmare frequency at home. CONCLUSIONS:Ketamine causes unpleasant dreams over the three post-administration nights. This may be evidence of a residual psychotogenic effect that is not found on standard self-report symptomatology measures or a result of disturbed sleep electrophysiology.
Authors: A Maksimow; M Särkelä; J W Långsjö; E Salmi; K K Kaisti; A Yli-Hankala; S Hinkka-Yli-Salomäki; H Scheinin; S K Jääskeläinen Journal: Clin Neurophysiol Date: 2006-06-27 Impact factor: 3.708
Authors: Hongjie Yuan; Scott J Myers; Gordon Wells; Katherine L Nicholson; Sharon A Swanger; Polina Lyuboslavsky; Yesim A Tahirovic; David S Menaldino; Thota Ganesh; Lawrence J Wilson; Dennis C Liotta; James P Snyder; Stephen F Traynelis Journal: Neuron Date: 2015-02-26 Impact factor: 17.173
Authors: Scott J Myers; Kamalesh P Ruppa; Lawrence J Wilson; Yesim A Tahirovic; Polina Lyuboslavsky; David S Menaldino; Zackery W Dentmon; George W Koszalka; Robert Zaczek; Raymond J Dingledine; Stephen F Traynelis; Dennis C Liotta Journal: J Pharmacol Exp Ther Date: 2021-09-07 Impact factor: 4.402
Authors: Riley E Perszyk; Zhaoshi Zheng; Tue G Banke; Jing Zhang; Lingling Xie; Miranda J McDaniel; Brooke M Katzman; Stephen C Pelly; Hongjie Yuan; Dennis C Liotta; Stephen F Traynelis Journal: Mol Pharmacol Date: 2021-03-09 Impact factor: 4.436
Authors: Santiago Castro-Zaballa; Matías Lorenzo Cavelli; Joaquin Gonzalez; Antonio Egidio Nardi; Sergio Machado; Cecilia Scorza; Pablo Torterolo Journal: Front Psychiatry Date: 2019-01-17 Impact factor: 4.157